Premaitha Share Discussion Threads

[gary38] 29/4/2016 19:09

I have chosen NIPT by buying their shares and see a min of 100% return on my investment with or without the on going irritation.

[blackss] 29/4/2016 17:53

Hardly a level playing field though. would you chose Prem over Illumina if you thought there was an excellent chance of ending up in court like Genoma ?

[gary38] 29/4/2016 16:49

So much depression, cheer up, the competition with or without no case would be the same for them as for us, one winner and one losser, so at the moment its the same and if no case there would still be the same competition .

[twix386] 29/4/2016 16:36

I agree BlackSS,

We thought Illumina wanted to string it out as long as possible and now we do their job for them and I am not impressed with the stated rationale which will be a help only if nothing changes on validity of patent meantime as Illumina secrure deals. I expect 540 to be overturned in USA and that must make EU patent landscape less favourable, even though different jurisdiction. Difficult to know anything for sure and as pushed into the future, but my gut feeling is the delay could potentially be very unhelpful in the long run.
Anti-trust and compensation all to the good as is Ariosa assuming the delay keeps that aspect relevant come Summer 2017. If we had Anti trust/damages with our October date, I would have loved that.

[hjb1] 29/4/2016 13:23

yes, and the so called "experts" said the "overhang" had gone and share price would climb..hmmm!?

[thinkbig?] 29/4/2016 13:18

I think you will find there has been a sell order put in hence the sharpe drop on low volume

[blackss] 29/4/2016 11:53

Twix...when i said exactly that i got shouted down. the fact is that this delay till next summer plays straight into Illumina's hands and we have no guarantee there will not be further delays if they can spin it. All we can do is wait it out or sell up but as i said the other day the market has valued this at 10p and Prem valued themselves rather unhelpfully at 6.5p.

[timojelly] 29/4/2016 10:30

This patent sh1t will rumble on for years... By very nature of this sector. Let's move along and gain increased traction outside of Europe.

[hjb1] 29/4/2016 10:12

in any case allegedly it does not infringe the so called patent anyway, so what does it
matter?

" the patents held by Illumina are invalid and that, in any event, the IONA® test does not infringe them".

[captain_kurt] 29/4/2016 09:48

The risk now is Illumina will go after NIPT's other customers.

I doubt NIPTs will name anymore customers in future RNSs

[twix386] 29/4/2016 09:45

Ngen,

Can you please stop!

I think only then might we see a change of luck ;-)

Too many stale bulls and still a seller. No contract news for a month and Illumina getting support to overturn 540 in USA on High Court appeal.
We need to deliver and imv making the court case Summer 2017 just gives Illumina more time whilst we remain under the writ. If 540 overturned what point, our partnership with Ariosa - I think the delay may well not be a good decision and if we expected to win we should have won in October.

[timojelly] 29/4/2016 09:25

And we can now buy sub 10p.....

[ngen yap] 29/4/2016 07:57

Esperite results out. 1st year of Genoma, sales up €3.4m and growing 10% per month. Not all NIPT but very encouraging.

[dire cons] 27/4/2016 06:28

timo, looks as though they're already planning to branch out (in to oncology I believe), so they are not letting this Illumina fiasco distract them too much.

Interesting.

[twix386] 27/4/2016 02:35

not at 6.5p with a built in profit already and one of these guys pressumably offloading some, as still a seller.

Look, it's much better than RL, but adding at 6.5p - who wouldn't!! These guys aren't mugs ;-)

[dire cons] 26/4/2016 16:53

I'm surprised there wasn't much comment here regarding this;

Small cap hedge fund star David Newton has more than doubled his stake in prenatal healthcare specialist Premaitha Health (NIPT) as a number of earlier investors cash out.

Newton upped his holding to 12.7% of the company worth £2.9 million at a share price of 10p, down 62% over the last 12 months.

Premaitha provides non-invasive testing for Down’s syndrome. Previous tests required the extraction of amniotic fluid and returned a high percentage of false positives, the company claims.

The shares are held in his Helium Rising Stars fund. Newton told Citywire: ‘We have been greatly impressed with the rapid customer uptake of Premaitha’s Iona test and took this opportunity to significantly increase our investment.’

Also sharply upping his stake from below 5% to above 8% was small-cap guru Giles Hargreave. In an update this month Premaitha described take-up of its testing as ‘at the upper end’ of expectations. House broker Panmure Gordon rates the company a ‘buy’ on a target of 24p.

Surely these guys are no mugs?

[twix386] 26/4/2016 13:46

Ngen,

Yup, it's been superb and share price been one of the best parts! lol
we'll have to wait though - very true - another year to Summer 2017 with plenty of stale bulls capping the share price unless contract news is much better than the last year.

[ngen yap] 26/4/2016 13:39

Filter out the shenanigans on the share disposals and bullying tactics of Illumina (which is against almost everyone), we have a solid business which is getting significant traction - those who moaned at not being offered earlier placings, 10p is a good entry price. Happy to accummulate and wait.

[timojelly] 26/4/2016 07:28

Take a look at @PremaithaHealth's Tweet: https://twitter.com/PremaithaHealth/status/724617671837401088?s=09

[timojelly] 26/4/2016 07:27

https://en.m.wikipedia.org/wiki/Molecular_pathology

[gary38] 25/4/2016 13:29

A potential Reverse Head &Shoulders chart pattern forming on the daily chart H&S line 10.9 confirmation 11.2 objective 13.5. My plan is to add some more at 11.2.

[gary38] 25/4/2016 11:32

Brought 19395 shares to start with and will buy more on the way up .

[gary38] 25/4/2016 11:27

Just brought in here as NIPT have a great product.

[gpback] 25/4/2016 05:36

Giles Hargreave and ​Small cap hedge fund star David Newton up Stakes in Premaitha Health (NIPT)
Published: Monday, 25 April 2016